Popert R J, Joyce A D, Thomas D J, Walmsley B H, Coptcoat M J
Department of Urology, King's College Hospital, London.
Br J Urol. 1993 Mar;71(3):279-83. doi: 10.1111/j.1464-410x.1993.tb15943.x.
Nineteen patients with newly diagnosed transitional cell carcinoma of the bladder consented to receive an intravenous bolus of bromodeoxyuridine (BrdUrd) 3 to 6 h prior to transurethral resection of bladder tumour. Routine paraffin embedded sections were stained with anti-BrdUrd monoclonal antibody in order to determine the S phase fraction of the bladder tumours and to correlate this with tumour grade, category and the development of recurrence during follow-up. BrdUrd labelling of nuclei was reliably detected in 100% of the tumours. The mean labelling index of Ta tumours (n = 8) was 3.14%; in T1 tumours (n = 7) it was 8.6% and in T2-3 tumours (n = 4) it was 16.4%. A similar correlation was found in association with tumour grade. The patients were followed up for a mean of 23 months (range 18-30). Seven of the 15 superficial tumours recurred during the period of follow-up. These tumours had a mean labelling index (at diagnosis) of 8.4%, whereas the tumours that did not recur had a mean labelling index of 3.4%. The in vivo determination of BrdUrd uptake in transitional cell carcinoma of the bladder may be useful in predicting which superficial tumours are likely to recur following resection and so rationalise both the time to follow-up and intravesical chemoprophylaxis.
19例新诊断的膀胱移行细胞癌患者同意在经尿道膀胱肿瘤切除术前3至6小时接受静脉注射溴脱氧尿苷（BrdUrd）。常规石蜡包埋切片用抗BrdUrd单克隆抗体染色，以确定膀胱肿瘤的S期分数，并将其与肿瘤分级、类别以及随访期间复发的发生情况相关联。在100%的肿瘤中均能可靠地检测到细胞核的BrdUrd标记。Ta期肿瘤（n = 8）的平均标记指数为3.14%；T1期肿瘤（n = 7）为8.6%，T2 - 3期肿瘤（n = 4）为16.4%。在肿瘤分级方面也发现了类似的相关性。患者平均随访23个月（范围18 - 30个月）。15例浅表性肿瘤中有7例在随访期间复发。这些复发肿瘤（诊断时）的平均标记指数为8.4%，而未复发的肿瘤平均标记指数为3.4%。体内测定膀胱移行细胞癌中BrdUrd的摄取情况可能有助于预测哪些浅表性肿瘤切除后可能复发，从而使随访时间和膀胱内化学预防更加合理。
